This prospective study evaluated the clinical outcomes of second-generation patient-specific focal talar resurfacing for the treatment of symptomatic osteochondral lesions of the talus. Twenty patients underwent implantation of a customized resurfacing implant and were followed for up to 24 months to assess pain relief, functional recovery, quality of life, return to sport and work, and treatment safety.

The results demonstrated significant and sustained improvements in patient-reported outcomes, with marked reductions in pain and substantial gains in ankle function. Most patients successfully returned to sports within approximately five months and resumed work after about four months. Only one treatment failure requiring revision surgery was observed, resulting in a low failure rate of 5%.

Overall, patient-specific talar resurfacing appears to be a safe and effective treatment option for carefully selected patients with osteochondral lesions of the talus, providing durable improvements in pain, function, and quality of life over the first two years after surgery. Further studies with larger patient populations and longer follow-up are needed to confirm these encouraging findings.